

January 1-October 2, 2020 Gram Positive organisms	Isolates	Penicillins				Ceph 1st Gen	Ceph 3rd Gen	Ceph 4th Gen	Glycopeptides	Quinolones		Miscellaneous Antibiotics					Tetracyclines	Synergy Antibiotics	
		Ampicillin	Ampicillin-Sulbactam	Oxacillin	Penicillin	Cefazolin	Ceftriaxone	Cefepime	Vancomycin	Ciprofloxacin	Levofloxacin	Clindamycin	Daptomycin	Linezolid	Rifampin	Sulfamethoxazole-Trimethoprim	Tetracycline	Gentamicin Synergy	Streptomycin Synergy
<b>All Specimen Sources</b>																			
Enterococcus faecalis	70	100% (70/70)	^	R	100% (70/70)	R	R	R	100% (69/69)	90% (63/70)	99% (69/70)	R	100%* (20/20)	96% (67/70)		R	NR	86% (60/70)	99% (69/70)
Methicillin Susceptible Staphylococcus aureus (MSSA)	340	NR	100% (340/340)	100% (340/340)	NR	§	§	§	100% (340/340)	88% (299/340)	91% (311/340)	81%■ (262/324)	100% (331/331)	100% (338/338)	98% (335/340)	98% (338/340)	92% (307/333)	NR	NR
Methicillin resistant Staphylococcus aureus (MRSA)	206	NR	NR	NR	NR	NR	NR	NR	100% (206/206)	43% (89/206)	46% (95/206)	87%■ (179/206)	100% (192/192)	100% (202/202)	99% (203/206)	99% (192/206)	93% (192/206)	NR	NR
Staphylococcus epidermidis	58	NR	40% (23/58)	40% (23/58)	NR	§	§	§	100% (58/58)	73% (42/58)	83% (48/58)	63% (32/51)	100% (39/39)	100% (58/58)	99% (57/58)	67% (38/57)	93% (38/39)	NR	NR
Streptococcus agalactiae (Group B Streptococcus)	34	◇			100% (34/34)				100% (34/34)	NR					NR	NR	NR		
Streptococcus pneumoniae (non-CSF)	187	◇		33% (62/187)	99% (187/189)		97% (181/187)		100% (187/187)	NR		77% (143/187)			100% (187/187)	NR	NR	R	R
Streptococcus viridans group	44			NR	80% (59/73)	NR	91% (40/44)	69%* (9/13)	100% (44/44)	NR		87% (38/44)			NR	NR	NR	R	R

\* Data for fewer than 30 isolates per organism, per selected time frame is not statistically significant according to CLSI standards.

^ susceptibility inferred from ampicillin

§ susceptibility inferred from oxacillin/cefazolin

R=resistant due to intrinsic or acquired resistance

NR=not recommended

◇ susceptibility inferred from penicillin

■ Cindamycin susceptibility for skin and soft tissue specimens: MSSA 80% (88/110) and MRSA 98% (89/91)

January 1-October 2, 2020 Gram Negative organisms	Isolates	Penicillins			Ceph 1st Gen	Ceph 2nd Gen	Ceph 3rd Gen		Ceph 4th Gen	Carbapenems			Aminoglycosides			Quinolones		Miscellaneous	
		Ampicillin	Ampicillin-Sulbactam	Piperacillin-Tazobactam	Cefazolin	Cefuroxime	Ceftazidime	Ceftriaxone	Cefepime	Ertapenem	Imipenem-Cilastatin	Meropenem	Amikacin	Gentamicin	Tobramycin	Ciprofloxacin	Levofloxacin	Nitrofurantoin	Sulfamethoxazole-Trimethoprim
<b>All Specimen Sources</b>																			
Enterobacter cloacae *	41	R	R	93% (38/41)	R	NR	94%* (29/31)	85%* (35/41)	98%* (40/41)	93% (38/41)	87% (27/31)	100% (41/41)	100% (41/41)	100% (31/31)	98% (40/41)	98% (40/41)	100% (41/41)		83% (34/41)
Escherichia coli, non-ESBL <sup>Δ</sup>	370	53% (196/368)	58% (213/368)	98% (359/368)	93% (319/343)	100% (127/127)	100% (127/127)	100% (366/367)	100% (366/367)	100% (368/368)	100% (127/127)	100% (368/368)	100% (368/368)	94% (119/127)	96% (354/368)	90% (333/368)	92% (338/368)	99% (240/243)	75% (277/368)
Haemophilus influenzae	218				NR	96% (210/218)		99% (216/218) <sup>§</sup>											62% (135/218)
Klebsiella oxytoca	32	R	56% (18/32)	88% (28/32)	64%* (9/14)	95%* (18/19)	100%* (19/19)	96%* (27/28)	100%* (28/28)	100% (32/32)	96%* (22/23)	97% (31/32)	97% (31/32)	83%* (19/23)	88% (28/32)	91% (29/32)	100% (32/32)	89%* (8/9)	88% (28/32)
Klebsiella pneumoniae, non-ESBL <sup>Δ</sup>	73	R	77% (56/73)	96% (70/73)	96% (64/67)	88% (35/40)	100% (40/40)	99% (72/73)	100% (73/73)	99% (72/73)	100% (40/40)	100% (73/73)	99% (72/73)	98% (39/40)	96% (70/73)	96% (70/73)	100% (73/73)	15% (5/33)	85% (62/73)
Proteus mirabilis	50	86% (43/50)	96% (48/50)	100% (50/50)	98% (45/46)	100%* (25/25)	100%* (25/25)	100% (50/50)	100% (50/50)	100% (50/50)		100% (50/50)	98% (49/50)	100%* (25/25)	100% (50/50)	96% (48/50)	96% (48/50)	R	92% (46/50)
Pseudomonas aeruginosa (CF and non-CF) *	156	R	R	88% (137/156)	R	R	93% (124/134)	R	84% <sup>#</sup> (131/156)	R	86% (115/134)	92% (143/155)	91% (142/156)	71% (95/134)	92% (144/156)	91% (142/156)	94% (146/156)	R	R
Salmonella spp.	56	95% (53/56)	96% (54/56)	100% (56/56)	NR	NR	98% (55/56)	96% (54/56)	100% (56/56)	98% (55/56)	100% (56/56)	100% (56/56)	NR	NR	NR		98% (55/56)	NR	100% (56/56)
Serratia marcescens	18*	R	R	89%* (16/18)	R	R	89%* (16/18)	61%* (11/18)	89%* (16/18)	78%* (14/18)	67%* (12/18)	89%* (16/18)	78%* (14/18)	67%* (12/18)	56%* (10/18)	67%* (12/18)	89%* (16/18)	R	83%* (15/18)
Stenotrophomonas maltophilia	42	R	R	R	R	R	33% (14/42)	R	NR	R	R	R	R	R	R	NR	93% (39/42)	R	98% (41/42)

\* Ceftriaxone and Ceftazidime should be avoided for the treatment of infections caused by E.cloacae, even if they test susceptible. Empiric cefepime is recommended.

\* Data for fewer than 30 isolates per organism, per selected time frame is not statistically significant according to CLSI standards.

<sup>Δ</sup> ESBL producing organisms: n=21 (15 E.coli, 6 K.pneumoniae). 2 were blood (both E.coli) , 12 urine

<sup>§</sup> Susceptibility inferred from cefotaxime

<sup>#</sup>Of the 25 cefepime non-susceptible PSA isolates, 9 are isolates from CF patients, 5 are isolates from tracheostomy specimens, 4 from sputum specimens (blood specimens=0)

R = resistant due to intrinsic resistance

NR = not recommended